NKTX Nkarta, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 10, 2026
$2.58
· of 52w range
· above low
· to high
$1.7052w low
$3.7252w high
Market Cap
$183M
P/E
-1.8
EPS
$-1.41
Revenue
$0
your badges
52W Range
$2–$4
Analyst Rating
BUY
Price Target
$11
P/E
-1.8
ROE
-31.1%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
NKTX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.58
Market Cap
$183M
P/E
-1.8
EPS
$-1.41
Revenue
$0
ROE
-31.1%
52W Range
$2–$4
NKTX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$02019-12-31 → 2025-12-31
EPS$-1.412021-12-31 → 2025-12-31
Free Cash Flow$-90M2020-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | NKTX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -1.85Y avg ≈-2.8 | ≈-2.8 | · | · | |
| P/B | 0.65Y avg ≈1.0 | ≈1.0 | 3.6 | Undervalued | |
| Price / FCF | -2.05Y avg ≈-3.1 | ≈-3.1 | · | · | |
| Price / Cash Flow | -2.15Y avg ≈-3.9 | ≈-3.9 | · | · | |
| Price / Tangible Book | 0.65Y avg ≈1.0 | ≈1.0 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | NKTX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -23.0%5Y avg ≈-26.8% | ≈-26.8% | -31.6% | Top tier | |
| ROE | -31.1%5Y avg ≈-32.2% | ≈-32.2% | -70.9% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | NKTX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 8.05Y avg ≈14.7 | ≈14.7 | 7.9 | In line | |
| Quick Ratio | 12.45Y avg ≈14.3 | ≈14.3 | 6.3 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | NKTX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.0 | ≈0.0 | 0.1 | Weak | |
| Revenue / Employee | ≈$0.00 | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-1.1%
Next Report
Nov 09, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 10, 2026 | $-0.54 | $-0.38 | -40.8% |
| March 31, 2026 | May 12, 2026 | $-0.37 | $-0.38 | 2.6% |
| Dec. 31, 2025 | $-0.37 | $-0.32 | -14.1% | |
| Sept. 30, 2025 | $-0.29 | $-0.32 | 9.3% | |
| June 30, 2025 | $-0.31 | $-0.36 | 14.4% | |
| March 31, 2025 | $-0.43 | $-0.45 | 4.2% | |
| Dec. 31, 2024 | $-0.35 | $-0.42 | 16.9% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | · | · | $0 | · | $115.0K | |
| R&D Expense | $90M | $97M | $97M | $91M | $63M | $36M | $17M | |
| SG&A Expense | $32M | $31M | $35M | $28M | $23M | $15M | $5M | |
| Operating Expenses | $122M | $128M | $132M | $119M | $86M | $52M | $22M | |
| Operating Income | $-122M | $-128M | $-132M | $-119M | $-86M | $-52M | $-22M | |
| Other Non-op | $2M | $87.0K | $42.0K | $-470.0K | $-16.0K | $-3.0K | $18.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-104M | $-109M | $-118M | $-114M | $-86M | $-91M | $-21M | |
| EPS (Basic) | $-1.41 | $-1.60 | $-2.40 | $-2.61 | $-2.62 | · | · | |
| EPS (Diluted) | $-1.41 | $-1.60 | $-2.40 | $-2.61 | $-2.62 | · | · | |
| Shares (Basic) | 73,991,197 | 67,865,323 | 49,014,300 | 43,631,722 | 32,856,883 | · | · | |
| Shares (Diluted) | 73,991,197 | 67,865,323 | 49,014,300 | 43,631,722 | 32,856,883 | · | · | |
| EBITDA | $-113M | $-119M | $-126M | $-116M | $-85M | $-51M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $40M | $28M | $31M | $37M | $61M | $97M | $21M | |
| Short-term Investments | $237M | $239M | $217M | $315M | $177M | $218M | $16M | |
| Prepaid Expense | $6M | $6M | $5M | $9M | $8M | $4M | $474.0K | |
| Other Current Assets | $2M | $3M | $2M | $3M | $3M | $1M | $67.0K | |
| Current Assets | $283M | $273M | $253M | $361M | $246M | $319M | $37M | |
| PP&E (Net) | $67M | $75M | $79M | $62M | $13M | $9M | $3M | |
| PP&E (Gross) | $96M | $96M | $91M | $68M | $16M | $11M | $4M | |
| Accum. Depreciation | $29M | $21M | $12M | $6M | $3M | $1M | $645.0K | |
| Other Non-current Assets | $2M | $4M | $4M | $2M | $1M | $547.0K | $455.0K | |
| Total Assets | $404M | $501M | $379M | $473M | $274M | $338M | $48M | |
| Accounts Payable | $2M | $638.0K | $4M | $2M | $1M | $1M | $2M | |
| Accrued Liabilities | $13M | $12M | $14M | $16M | $9M | $6M | $3M | |
| Current Liabilities | $22M | $19M | $23M | $22M | $13M | $9M | $8M | |
| Capital Leases | $70M | $74M | $82M | $79M | $10M | $8M | $6M | |
| Other Non-current Liabilities | $87.0K | $87.0K | · | · | $18.0K | $82.0K | $134.0K | |
| Total Liabilities | $92M | $93M | $106M | $101M | $23M | $16M | $14M | |
| Common Stock | $7.0K | $7.0K | $5.0K | $5.0K | $3.0K | $3.0K | $1.0K | |
| Retained Earnings | $-648M | $-544M | $-435M | $-318M | $-204M | $-118M | $-27M | |
| AOCI | $407.0K | $674.0K | $8.0K | $-679.0K | $-150.0K | $3.0K | $-2.0K | |
| Stockholders' Equity | $312M | $408M | $273M | $372M | $251M | $321M | $-25M | |
| Liabilities + Equity | $404M | $501M | $379M | $473M | $274M | $338M | $48M | |
| Shares Outstanding | 71,078,531 | 70,645,139 | 49,181,295 | 48,877,806 | 32,971,107 | 32,627,963 | 1,600,601 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $9M | $9M | $6M | $3M | $2M | $800.0K | $400.0K | |
| Stock-based Comp | $9M | $17M | $17M | $17M | $14M | $7M | $947.0K | |
| Restructuring | $5M | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-17M | $8M | $37M | $2M | $40M | · | |
| Operating Cash Flow | $-89M | $-100M | $-86M | $-57M | $-68M | $-44M | $-18M | |
| CapEx | $1M | $4M | $28M | $47M | $5M | $8M | $2M | |
| Investing Cash Flow | $100M | $-130M | $79M | $-185M | $33M | $-210M | $-18M | |
| Financing Cash Flow | $141.0K | $226M | $691.0K | $219M | $1M | $330M | $50M | |
| Net Change in Cash | $12M | $-3M | $-6M | $-23M | $-34M | $76M | $13M | |
| Free Cash Flow | $-90M | $-104M | $-114M | $-104M | $-73M | $-51M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| ROA | -23.0% | -24.7% | -27.6% | -30.5% | -28.1% | -47.3% | · | |
| ROE | -31.1% | -25.9% | -41.2% | -29.5% | -33.0% | -27.9% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.7 | 14.4 | 10.8 | 16.4 | 19.0 | 36.1 | · | |
| Quick Ratio | 12.4 | 14.1 | 10.6 | 16.0 | 18.4 | 35.7 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | · | 0.0 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.39 | $5.78 | $5.56 | $7.62 | $7.61 | $9.84 | · | |
| Revenue / Share | $0.00 | $0.00 | · | · | · | · | · | |
| Cash Flow / Share | $-1.20 | $-1.47 | $-1.76 | $-1.31 | · | · | · | |
| Cash / Share | $0.56 | $0.39 | $0.63 | $0.77 | $1.84 | $2.96 | · | |
| Dividend / Share | $0.00 | $0.00 | $0.00 | · | · | · | · | |
| EPS (TTM) | $-1.41 | $-1.60 | $-2.40 | $-2.61 | $-2.62 | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | · | $0 | · | · | |
| Net Income TTM | $-104M | $-109M | $-118M | $-114M | $-86M | $-91M | · | |
| Market Cap | $131M | $176M | $325M | $293M | $506M | $2.01B | · | |
| P/E | -1.3 | -1.6 | -2.8 | -2.3 | -5.9 | · | · | |
| P/B | 0.4 | 0.4 | 1.2 | 0.8 | 2.0 | 6.2 | · | |
| P / Tangible Book | 0.4 | 0.4 | 1.2 | 0.8 | 2.0 | 6.2 | · | |
| P / Cash Flow | -1.5 | -1.8 | -3.8 | -5.1 | -7.5 | -46.1 | · | |
| P / FCF | -1.5 | -1.7 | -2.8 | -2.8 | -6.9 | -39.3 | · | |
| Earnings Yield | -76.2% | -64.3% | -36.4% | -43.6% | -17.1% | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $29M | $25M | $25M | $20M | $21M | $24M | $23M | $25M | $23M | $25M | $23M | $22M | $25M | $26M | $27M | $23M | |
| SG&A Expense | $14M | $6M | $6M | $7M | $6M | $12M | $8M | $9M | $8M | $8M | $8M | $7M | $12M | $8M | $8M | $7M | |
| Operating Expenses | $43M | $31M | $31M | $27M | $27M | $37M | $31M | $34M | $31M | $33M | $31M | $29M | $37M | $34M | $35M | $30M | |
| Operating Income | $-43M | $-31M | $-31M | $-27M | $-27M | $-37M | $-31M | $-34M | $-31M | $-33M | $-31M | $-29M | $-37M | $-34M | $-35M | $-30M | |
| Other Non-op | $222.0K | $206.0K | $256.0K | $2M | $239.0K | $205.0K | $94.0K | $-3.0K | $-2.0K | $-2.0K | $-25.0K | $33.0K | $1.0K | $33.0K | $-489.0K | $17.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-40M | $-28M | $-27M | $-22M | $-23M | $-32M | $-26M | $-28M | $-25M | $-30M | $-28M | $-26M | $-33M | $-31M | $-33M | $-28M | |
| EPS (Basic) | $-0.54 | $-0.37 | $-0.38 | $-0.29 | $-0.31 | $-0.43 | $-0.29 | $-0.39 | $-0.34 | $-0.58 | $-0.57 | $-0.52 | $-0.68 | $-0.63 | $-0.63 | $-0.58 | |
| EPS (Diluted) | $-0.54 | $-0.37 | $-0.38 | $-0.29 | $-0.31 | $-0.43 | $-0.29 | $-0.39 | $-0.34 | $-0.58 | $-0.57 | $-0.52 | $-0.68 | $-0.63 | $-0.63 | $-0.58 | |
| Shares (Basic) | 74,494,855 | 74,257,973 | · | 74,024,543 | 73,977,625 | 73,916,477 | · | 73,563,316 | 73,494,523 | 50,682,469 | · | 49,062,799 | 48,970,391 | 48,921,326 | · | 48,630,328 | |
| Shares (Diluted) | 74,494,855 | 74,257,973 | · | 74,024,543 | 73,977,625 | 73,916,477 | · | 73,563,316 | 73,494,523 | 50,682,469 | · | 49,062,799 | 48,970,391 | 48,921,326 | · | 48,630,328 | |
| EBITDA | $-40M | $-29M | · | $-25M | $-25M | $-34M | · | $-31M | $-28M | $-30M | · | $-27M | $-36M | $-34M | · | $-30M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25M | $27M | $40M | $60M | $53M | $53M | $28M | $57M | $120M | $250M | $31M | $38M | $29M | $54M | $37M | $40M | |
| Short-term Investments | $158M | $203M | $237M | $222M | $236M | $213M | $239M | $226M | $204M | $187M | $217M | $237M | $252M | $270M | $315M | $353M | |
| Prepaid Expense | $5M | $5M | $6M | $7M | $7M | $6M | $6M | $7M | $7M | $5M | $5M | $6M | $6M | $9M | $9M | $9M | |
| Other Current Assets | · | · | $2M | · | · | · | $3M | · | · | · | $2M | $2M | $3M | $3M | $3M | $3M | |
| Current Assets | $188M | $236M | $283M | $289M | $297M | $272M | $273M | $290M | $332M | $443M | $253M | $281M | $287M | $332M | $361M | $401M | |
| PP&E (Net) | $57M | $64M | $67M | $68M | $70M | $73M | $75M | $76M | $78M | $79M | $79M | $78M | $76M | $70M | $62M | $30M | |
| PP&E (Gross) | $93M | $96M | $96M | $96M | $96M | $96M | $96M | $95M | $94M | $92M | $91M | $87M | $84M | $76M | $68M | $35M | |
| Accum. Depreciation | $36M | $31M | $29M | $28M | $25M | $23M | $21M | $19M | $16M | $14M | $12M | $9M | $7M | $7M | $6M | $5M | |
| Other Non-current Assets | $1M | $2M | $2M | $2M | $2M | $5M | $4M | $5M | $4M | $4M | $4M | $4M | $4M | $2M | $2M | $2M | |
| Total Assets | $338M | $372M | $404M | $427M | $448M | $471M | $501M | $532M | $554M | $577M | $379M | $406M | $429M | $458M | $473M | $504M | |
| Accounts Payable | $4M | $2M | $2M | $1M | $2M | $1M | $638.0K | $2M | $4M | $3M | $4M | $4M | $3M | $5M | $2M | $9M | |
| Accrued Liabilities | $12M | $10M | $13M | $11M | $11M | $11M | $12M | $14M | $12M | $13M | $14M | $15M | $18M | $15M | $16M | $12M | |
| Current Liabilities | $24M | $18M | $22M | $19M | $19M | $19M | $19M | $22M | $21M | $22M | $23M | $26M | $27M | $26M | $22M | $26M | |
| Capital Leases | $66M | $68M | $70M | $70M | $72M | $73M | $74M | $79M | $80M | $81M | $82M | $83M | $84M | $86M | $79M | $78M | |
| Other Non-current Liabilities | $87.0K | $87.0K | $87.0K | $87.0K | $87.0K | $87.0K | $87.0K | · | · | · | · | · | · | · | · | $5.0K | |
| Total Liabilities | $90M | $86M | $92M | $89M | $91M | $92M | $93M | $101M | $101M | $103M | $106M | $109M | $111M | $112M | $101M | $105M | |
| Common Stock | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | |
| Retained Earnings | $-717M | $-676M | $-648M | $-621M | $-599M | $-576M | $-544M | $-518M | $-490M | $-465M | $-435M | $-408M | $-382M | $-349M | $-318M | $-285M | |
| AOCI | $-425.0K | $-130.0K | $407.0K | $536.0K | $362.0K | $652.0K | $674.0K | $2M | $-263.0K | $-127.0K | $8.0K | $-409.0K | $-601.0K | $-174.0K | $-679.0K | $-1M | |
| Stockholders' Equity | $248M | $286M | $312M | $338M | $358M | $379M | $408M | $431M | $453M | $474M | $273M | $297M | $318M | $347M | $372M | $399M | |
| Liabilities + Equity | $338M | $372M | $404M | $427M | $448M | $471M | $501M | $532M | $554M | $577M | $379M | $406M | $429M | $458M | $473M | $504M | |
| Shares Outstanding | · | · | 71,078,531 | · | · | · | 70,645,139 | · | · | · | 49,181,295 | · | · | · | 48,877,806 | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $800.0K | $800.0K | $700.0K | $700.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $2M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $5M | $4M | $4M | |
| Restructuring | · | · | $-59.0K | $-26.0K | $-86.0K | $5M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-5M | · | · | · | $-3M | · | · | · | $-6M | · | · | · | $5M | · | · | |
| Operating Cash Flow | $-24M | $-28M | $-22M | $-19M | $-19M | $-30M | $-25M | $-25M | $-22M | $-29M | $-23M | $-20M | $-22M | $-21M | $-7M | $-15M | |
| CapEx | $183.0K | $413.0K | $560.0K | $-8.0K | $138.0K | $518.0K | $1M | $777.0K | $2M | $175.0K | $7M | $6M | $10M | $5M | $35M | $8M | |
| Investing Cash Flow | $21M | $16M | $1M | $25M | $19M | $54M | $-5M | $-39M | $-108M | $21M | $16M | $29M | $-3M | $37M | $5M | $-79M | |
| Financing Cash Flow | $676.0K | $6.0K | $64.0K | $0 | $77.0K | $0 | $184.0K | $2.0K | $-368.0K | $226M | $295.0K | $0 | $395.0K | $1.0K | $424.0K | $3M | |
| Net Change in Cash | $-2M | $-12M | $-20M | $7M | $816.0K | $25M | $-29M | $-63M | $-130M | $219M | $-7M | $9M | $-25M | $16M | $-2M | $-91M | |
| Free Cash Flow | · | $-29M | · | · | · | $-30M | · | · | · | $-29M | · | · | · | $-26M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -10.3% | -6.6% | · | -4.5% | -4.6% | -6.1% | · | -6.0% | -5.1% | -5.7% | · | -5.6% | -7.1% | -8.1% | · | -7.1% | |
| ROE | -13.3% | -8.4% | · | -5.7% | -5.7% | -7.5% | · | -7.8% | -6.5% | -7.2% | · | -7.4% | -9.0% | -10.7% | · | -8.5% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.0 | 13.0 | · | 15.2 | 15.7 | 14.5 | · | 12.9 | 15.9 | 20.0 | · | 11.0 | 10.8 | 12.8 | · | 15.2 | |
| Quick Ratio | 7.8 | 12.7 | · | 14.9 | 15.3 | 14.2 | · | 12.6 | 15.6 | 19.7 | · | 10.7 | 10.5 | 12.4 | · | 14.8 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow / Share | · | $-0.38 | · | · | · | $-0.40 | · | · | · | $-0.56 | · | · | · | $-0.42 | · | · | |
| EPS (TTM) | $-1.58 | $-1.35 | · | $-1.32 | $-1.42 | $-1.45 | · | $-1.88 | $-2.01 | $-2.35 | · | $-2.46 | $-2.52 | $-2.45 | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-117M | $-100M | · | $-103M | $-109M | $-111M | · | $-111M | $-108M | $-116M | · | $-122M | $-125M | $-119M | · | · | |
| P/E | -1.8 | -1.6 | · | -1.6 | -1.2 | -1.3 | · | -2.4 | -2.9 | -4.6 | · | -0.6 | -0.9 | -1.4 | · | · | |
| Earnings Yield | -55.8% | -64.0% | · | -63.8% | -85.5% | -78.8% | · | -41.6% | -34.0% | -21.7% | · | -177.0% | -115.1% | -69.0% | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | · | · | $0 |
| Net Income | $-104M | $-109M | $-118M | $-114M | $-86M |
| Diluted EPS | $-1.41 | $-1.60 | $-2.40 | $-2.61 | $-2.62 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 12.7 | 14.4 | 10.8 | 16.4 | 19.0 |
| Quick Ratio | 12.4 | 14.1 | 10.6 | 16.0 | 18.4 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-90M | $-104M | $-114M | $-104M | $-73M |
Institutional owners (13F) 146 filers · $167.8M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
146
Value held
$167.8M
New positions
27
Exited positions
13
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 27 (+5 vs prior Q) | 13 (+4 vs prior Q) | 51 (+4 vs prior Q) | 37 (+6 vs prior Q) | +230K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $30,578,515 | 10,805,129 | 18.23% | Shares |
| BlackRock, Inc. | $17,829,600 | 6,300,212 | 10.63% | Shares |
| NEA Management Company, LLC | $10,099,650 | 3,568,781 | 6.02% | Shares |
| SAMSARA BIOCAPITAL, LLC | $9,926,695 | 3,507,666 | 5.92% | Shares |
| SR One Capital Management, LP | $9,433,332 | 3,333,333 | 5.62% | Shares |
| GSK plc | $8,916,572 | 3,150,732 | 5.32% | Shares |
| Monaco Asset Management SAM | $6,716,722 | 2,373,400 | 4.00% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $6,300,754 | 2,226,415 | 3.76% | Shares |
| CITADEL ADVISORS LLC | $6,154,528 | 2,174,745 | 3.67% | Shares |
| TWO SIGMA INVESTMENTS, LP | $5,301,419 | 1,873,293 | 3.16% | Shares |
| VANGUARD GROUP INC | $4,805,134 | 2,597,370 | 2.86% | Shares |
| STATE STREET CORP | $3,639,688 | 1,286,109 | 2.17% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $3,638,743 | 1,285,507 | 2.17% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $3,332,755 | 1,177,652 | 1.99% | Shares |
| WASATCH ADVISORS LP | $3,329,257 | 1,577,847 | 1.98% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $2,983,530 | 1,054,251 | 1.78% | Shares |
| AWM Investment Company, Inc. | $2,563,980 | 906,000 | 1.53% | Shares |
| Blackstone Inc. | $2,114,135 | 747,044 | 1.26% | Shares |
| MARSHALL WACE, LLP | $1,904,620 | 673,010 | 1.14% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $1,650,595 | 583,249 | 0.98% | Shares |
| JPMORGAN CHASE & CO | $1,604,493 | 562,980 | 0.96% | Shares |
| Peapod Lane Capital LLC | $1,556,282 | 549,923 | 0.93% | Shares |
| Alyeska Investment Group, L.P. | $1,372,097 | 484,840 | 0.82% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $1,367,703 | 483,211 | 0.82% | Shares |
| Nuveen, LLC | $1,328,840 | 469,555 | 0.79% | Shares |
| GOLDMAN SACHS GROUP INC | $1,228,169 | 433,982 | 0.73% | Shares |
| TWO SIGMA ADVISERS, LP | $1,197,320 | 647,200 | 0.71% | Shares |
| NORTHERN TRUST CORP | $1,051,133 | 371,425 | 0.63% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $985,366 | 348,186 | 0.59% | Shares |
| MILLENNIUM MANAGEMENT LLC | $915,955 | 323,659 | 0.55% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $854,422 | 301,916 | 0.51% | Shares |
| XTX Topco Ltd | $820,658 | 289,985 | 0.49% | Shares |
| MORGAN STANLEY | $746,479 | 263,773 | 0.44% | Shares |
| Invesco Ltd. | $586,701 | 207,315 | 0.35% | Shares |
| IEQ CAPITAL, LLC | $501,017 | 177,038 | 0.30% | Shares |
| D. E. Shaw & Co., Inc. | $459,900 | 162,509 | 0.27% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $370,659 | 130,975 | 0.22% | Shares |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $367,900 | 130,000 | 0.22% | Shares |
| FMR LLC | $367,736 | 129,942 | 0.22% | Shares |
| Susquehanna Portfolio Strategies, LLC | $357,539 | 126,339 | 0.21% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $347,524 | 122,800 | 0.21% | Shares |
| BARCLAYS PLC | $344,042 | 121,570 | 0.21% | Shares |
| Qube Research & Technologies Ltd | $341,889 | 120,809 | 0.20% | Shares |
| MACKENZIE FINANCIAL CORP | $325,985 | 115,189 | 0.19% | Shares |
| Bank of New York Mellon Corp | $324,978 | 114,833 | 0.19% | Shares |
| JANE STREET GROUP, LLC | $315,899 | 111,625 | 0.19% | Shares |
| Point72 Asset Management, L.P. | $302,261 | 106,806 | 0.18% | Shares |
| Man Group plc | $283,133 | 100,047 | 0.17% | Shares |
| AMERICAN CENTURY COMPANIES INC | $268,428 | 94,851 | 0.16% | Shares |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $233,922 | 82,658 | 0.14% | Shares |
Activists & 5%+ owners 5 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| New Enterprise Associates 15, L.P., NEA Partners 15, L.P., NEA 15 GP, LLC, Forest Baskett, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, Scott D. Sandell ×4 filings | May 19, 2026 | 4.90% | Amendment | Passive investment | SEC |
| Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Srinivas Akkaraju ×4 filings | Nov. 24, 2025 | 4.90% | Amendment | · | SEC |
| LSP 6 Management B.V., LSP 6 Holding C.V., LSP 6 NK Holding B.V ×3 filings | Feb. 12, 2025 | 4.00% | Amendment | · | SEC |
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. ×3 filings | March 29, 2024 | · | Initial filing | · | SEC |
| Novo Holdings A/S ×4 filings | June 3, 2022 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 28 insiders · 10 officers · 11 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Paul J Hastings | Chief Executive Officer | June 18, 2026 S | 390,247 | 0 | 2 | $-58,728 |
| Matthew Plunkett | Chief Financial Officer | July 9, 2020 A | · | 0 | 0 | $0 |
| Nadir Mahmood | President | Jan. 15, 2026 S | 167,727 | 0 | 1 | $-11,693 |
| Shawn Marshall Rose | Chief Medical Officer, Head of Research & Development | Jan. 6, 2026 A | 70,000 | 0 | 0 | $0 |
| Alyssa Levin | Chief Financial and Business Officer | Jan. 15, 2025 S | 102,662 | 0 | 0 | $0 |
| David Shook | Chief Medical Officer, Head of Research & Development | Jan. 15, 2025 S | 190,955 | 0 | 0 | $0 |
| Ralph Brandenberger | Chief Technical Officer | Jan. 15, 2025 S | 124,796 | 0 | 0 | $0 |
| Alicia J. Hager | Chief Legal Officer | Jan. 15, 2025 S | 146,735 | 0 | 0 | $0 |
| James Trager | Chief Scientific Officer | June 18, 2024 S | 150,959 | 0 | 0 | $0 |
| Kanya Rajangam | Chief Medical Officer | Jan. 14, 2022 A | 12,800 | 0 | 0 | $0 |
| George Vratsanos | Director | June 10, 2026 A | · | 0 | 0 | $0 |
| Zachary Scheiner | Director | June 10, 2026 A | · | 0 | 0 | $0 |
| Angela Thedinga | Director | June 10, 2026 A | · | 0 | 0 | $0 |
| Ali Behbahani | Director | June 10, 2026 A | · | 0 | 0 | $0 |
| Michael Dybbs | Director | June 10, 2026 A | · | 0 | 0 | $0 |
| Simeon George | Director | June 10, 2026 A | 451,659 | 0 | 0 | $0 |
| Leone D Patterson | Director | June 10, 2026 A | · | 0 | 0 | $0 |
| Fouad Oscar Azzam | Director | June 7, 2023 A | · | 0 | 0 | $0 |
| Tiba Aynechi | Director | June 8, 2022 A | · | 0 | 0 | $0 |
| Laura Shawver | Director | June 8, 2022 A | · | 0 | 0 | $0 |
| Mohamad Makhzoumi | 10% owner | July 14, 2020 C | 2,902,115 | 0 | 0 | $0 |
| Anthony A. Florence, Jr. | 10% owner | July 14, 2020 C | 2,902,115 | 0 | 0 | $0 |
| Peter W. Sonsini | 10% owner | July 14, 2020 C | 2,902,115 | 0 | 0 | $0 |
| Novo Holdings A/S | 10% owner | July 14, 2020 C | 2,793,865 | 0 | 0 | $0 |
| Forest Baskett | 10% owner | July 14, 2020 C | 2,902,115 | 0 | 0 | $0 |
| Scott D. Sandell | 10% owner | July 14, 2020 C | 2,902,115 | 0 | 0 | $0 |
| Joshua Makower | 10% owner | July 14, 2020 C | 2,902,115 | 0 | 0 | $0 |
| GSK plc | · | July 14, 2020 A | 3,150,732 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 17 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.08% | 80,111 SH | Oct. 2, 2026 | Daily |
| IWC · iShares Trust | 0.03% | 149,326 SH | Sept. 11, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 38,962 SH | Aug. 19, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.01% | 101,133 SH | Oct. 2, 2026 | Daily |
| IWM · iShares Trust | 0.00% | 1,123,160 SH | Sept. 11, 2026 | Daily |
| RSSL · Global X Funds | 0.00% | 21,336 NS | July 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.00% | 145,492 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.00% | 3,413 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 6,031 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 17,065 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.00% | 8,973 SH | Sept. 3, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 599,527 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,567,021 SH | Aug. 19, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.00% | 259,168 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,786 SH | Aug. 19, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.00% | 6,442 NS | July 31, 2026 | N-PORT |
| IWN · iShares Trust | · | 452,090 SH | Sept. 11, 2026 | Daily |
NKTX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 13 analysts
BUY
Median target
$10.50
+307.8%
4 30.8%
Strong Buy
8 61.5%
Buy
1 7.7%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
6 analysts · 2026-10-03Mean target $10.83 +320.7%
← Below all targets
Current price $2.58
Low$9.00
Mean$10.83
High$14.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| NKTX | $131M | -1.3 | · | · | -31.1% | · |
| TRDA | $394M | -3.0 | -87.9% | -565.5% | -41.9% | · |
| WHWK | $114M | -7.3 | -72.5% | -288.3% | -13.4% | · |
| ALEC | $172M | -1.1 | -79.1% | -679.2% | -280.7% | · |
| ELDN | $114M | -2.9 | · | · | -69.4% | · |
| CUE | $29M | -1.1 | 195.8% | -96.9% | -119.3% | · |
| CHRS | $172M | 1.0 | 59.8% | 398.4% | 185.8% | · |
| CNTN | $112M | -2.7 | · | · | -18.0% | · |
| PYXS | $72M | -0.9 | -14.2% | -574.5% | -112.9% | · |
| DTIL | $100M | -1.2 | -50.1% | -133.4% | -72.4% | · |
| ALXO | $61M | -0.6 | · | · | -225.0% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 10, 2026